(Q77795103)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9888698%20AND%20SRC:MED&resulttype=core&format=json

8 December 2019

review article

1 reference

title

Immunocytokines: a promising approach to cancer immunotherapy (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9888698%20AND%20SRC:MED&resulttype=core&format=json

8 December 2019

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9888698%20AND%20SRC:MED&resulttype=core&format=json

8 December 2019

author name string

R Xiang

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9888698%20AND%20SRC:MED&resulttype=core&format=json

8 December 2019

J C Becker

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9888698%20AND%20SRC:MED&resulttype=core&format=json

8 December 2019

S D Gillies

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9888698%20AND%20SRC:MED&resulttype=core&format=json

8 December 2019

R A Reisfeld

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9888698%20AND%20SRC:MED&resulttype=core&format=json

8 December 2019

publication date

1 December 1998

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9888698%20AND%20SRC:MED&resulttype=core&format=json

Pharmacology & Therapeutics

8 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9888698%20AND%20SRC:MED&resulttype=core&format=json

8 December 2019

volume

80

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9888698%20AND%20SRC:MED&resulttype=core&format=json

8 December 2019

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9888698%20AND%20SRC:MED&resulttype=core&format=json

8 December 2019

page(s)

277-292

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9888698%20AND%20SRC:MED&resulttype=core&format=json

T cell-mediated eradication of murine metastatic melanoma induced by targeted interleukin 2 therapy

8 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900033-3

7 January 2021

An antibody-interleukin 2 fusion protein overcomes tumor heterogeneity by induction of a cellular immune response

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900033-3

7 January 2021

Long-lived and transferable tumor immunity in mice after targeted interleukin-2 therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900033-3

7 January 2021

A phase I/IB trial of murine monoclonal anti-GD2 antibody 14.G2a plus interleukin-2 in children with refractory neuroblastoma: a report of the Children's Cancer Group

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900033-3

7 January 2021

Expression of genetically engineered immunoconjugates of lymphotoxin and a chimeric anti-ganglioside GD2 antibody

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900033-3

7 January 2021

Antibody-targeted interleukin 2 stimulates T-cell killing of autologous tumor cells

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900033-3

7 January 2021

Neuronal properties of hybrid neuroblastoma X sympathetic ganglion cells

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900033-3

7 January 2021

Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900033-3

7 January 2021

Lymphokine-activated killer cell phenomenon. II. Precursor phenotype is serologically distinct from peripheral T lymphocytes, memory cytotoxic thymus-derived lymphocytes, and natural killer cells

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900033-3

7 January 2021

The enigma of the natural killer cell

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900033-3

7 January 2021

A phase I study of neuroblastoma with the anti-ganglioside GD2 antibody 14.G2a

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900033-3

7 January 2021

A phase I study of human/mouse chimeric antiganglioside GD2 antibody ch14.18 in patients with neuroblastoma

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900033-3

7 January 2021

Lymphokine-activated killer cells targeted by monoclonal antibodies to the disialogangliosides GD2 and GD3 specifically lyse human tumor cells of neuroectodermal origin

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900033-3

7 January 2021

The immunodominant major histocompatibility complex class I-restricted antigen of a murine colon tumor derives from an endogenous retroviral gene product

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900033-3

7 January 2021

Regression of cutaneous metastatic melanoma by intralesional injection with human monoclonal antibody to ganglioside GD2.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900033-3

7 January 2021

Targeted interleukin-2 therapy for spontaneous neuroblastoma metastases to bone marrow

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900033-3

7 January 2021

Interleukin-2 in cancer treatment: disappointing or (still) promising? A review

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900033-3

7 January 2021

Priming of tumor-specific T cells in the draining lymph nodes after immunization with interleukin 2-secreting tumor cells: three consecutive stages may be required for successful tumor vaccination

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900033-3

7 January 2021

The TGF-beta family of growth and differentiation factors.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900033-3

7 January 2021

Phase I trial of murine monoclonal antibody 14G2a administered by prolonged intravenous infusion in patients with neuroectodermal tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900033-3

7 January 2021

Clinical strategies for the treatment of neuroblastoma

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900033-3

7 January 2021

Eradication of established hepatic human neuroblastoma metastases in mice with severe combined immunodeficiency by antibody-targeted interleukin-2

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900033-3

7 January 2021

Paracrine cytokine adjuvants in cancer immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900033-3

7 January 2021

Is chronic graft versus host disease an autoimmune disease?

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900033-3

7 January 2021

Recognition events that inhibit and activate natural killer cells

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900033-3

7 January 2021

Natural killer cell receptors: the offs and ons of NK cell recognition.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900033-3

7 January 2021

Recombinant antibody fusion proteins for cancer immunotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900033-3

7 January 2021

Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma. German Cancer Aid 17-1A Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900033-3

7 January 2021

Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900033-3

7 January 2021

Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900033-3

7 January 2021

Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900033-3

7 January 2021

Modulation of T-cell function by gliomas

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900033-3

7 January 2021

Gene therapy for cancer: what have we done and where are we going?

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900033-3

7 January 2021

Factors, including transforming growth factor beta, released in the glioblastoma residual cavity, impair activity of adherent lymphokine-activated killer cells.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900033-3

7 January 2021

A recombinant antibody-interleukin 2 fusion protein suppresses growth of hepatic human neuroblastoma metastases in severe combined immunodeficiency mice

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900033-3

7 January 2021

Models of T cell anergy: is there a common molecular mechanism?

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900033-3

7 January 2021

Antigen-presenting cells. Professionals and amateurs

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900033-3

7 January 2021

Experts call for action to prevent colon cancer deaths by spurring screening awareness

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900033-3

7 January 2021

Idiotype/granulocyte-macrophage colony-stimulating factor fusion protein as a vaccine for B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900033-3

7 January 2021

Mechanism of interleukin-2 signaling: mediation of different outcomes by a single receptor and transduction pathway

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900033-3

7 January 2021

Interleukin-10 inhibits tumor metastasis through an NK cell-dependent mechanism

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900033-3

7 January 2021

10.1016/S0163-7258(98)00033-3

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9888698%20AND%20SRC:MED&resulttype=core&format=json

8 December 2019

1 reference